Effect of E-2-(4'-methoxybenzylidene)-1-benzosuberone on the 7,12-dimethylbenz [a] anthracene-induced Onco/Suppressor gene action in vivo I: A 24-hour experiment

Anticancer Research

Volumn 20, Issue 1 A, 2000, Pages 475-481

  Perjési, Pal ^a   Bayer, Zsuzsanna ^a   Ember, István ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

7,12 dimethylbenz a anthracene; c myc; E 2 (4' methoxybenzylidene) 1 benzosuberone; Gene expression; Ha ras; p53

Indexed keywords

2 (4' METHOXYBENZYLIDENE) 1 BENZOSUBERONE; ANTINEOPLASTIC AGENT; CHALCONE DERIVATIVE; DIMETHYLBENZ[A]ANTHRACENE; PROTEIN P53; RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; KIDNEY; LIVER; LUNG; LYMPH NODE; MOUSE; NONHUMAN; ONCOGENE C MYC; ONCOGENE H RAS; PRIORITY JOURNAL; SPLEEN; THYMUS; TUMOR SUPPRESSOR GENE;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANISOLES; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; BONE MARROW; CARCINOGENS; CYCLOHEPTANES; FEMALE; GENE EXPRESSION REGULATION; GENES, MYC; GENES, P53; GENES, RAS; KIDNEY; LUNG; LYMPH NODES; MICE; MICE, INBRED CBA; MOLECULAR STRUCTURE; ORGAN SPECIFICITY; PROTO-ONCOGENE PROTEINS C-MYC; PROTO-ONCOGENE PROTEINS P21(RAS); RNA, MESSENGER; SPLEEN; THYMUS GLAND; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0342749274     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Stuessy TF, Crawford DJ: Flavonoids and phylogenetic reconstruction. Plant Systematics and Evolution 143: 83-107, 1983.
2. Post JFM and Varma RS: Growth inhibitory effects of bioflavonoids and related compounds on human leukemic CEM-C1 and CEM-C7 cells. Cancer Letters 67: 207-213, 1992.
3. Beutler JA, Cardellina JH, Gray GN, Prather TR, Shoemaker RH, Boyd MR, Lin CM, Hamel E, Cragg GM: Two new cytotoxic chalcones from Calythropsis Aurea. J Natural Products 56: 1718-1722, 1993.
4. Yit CC, Das NP: Cytotoxic effect of butein on human colon adenocarcinoma cell proliferation. Cancer Letters 82: 65-72, 1994.
5. Shibata S: Anti-tumorigenic chalcones. Stem Cells 12: 44-52, 1994.
6. Edwards ML, Stemerick DM, Sunkara PS: Chalcones: A new class of antimitotic agents. J Med Chem 33: 1948-1954, 1990.
7. Wattenberg LW, Coccia JB, Galbraith AR: Inhibition of carcinogeninduced pulmonary and mammary carcinogenesis by chalcone administered subsequent to carcinogen exposure. Cancer Letters 83: 165-169, 1994.
8. Anto RJ, Sukumaran K, Kuttan G, Rao MNA, Subbaraju V, Kuttan R: Anticancer and antioxidant activity of synthetic chalcones and related compounds. Cancer Letters 97: 33-37, 1995.
9. Makita H, Tanaka T, Fujitsuka H, Tatematsu N, Satoh K, Hara A, Mori H: Chemoprevention of 4-nitroquinoline-1-oxide-induced rat oral carcinogenesis by dietary flavonoids, chalcone. 2-hydroxychalcone and quercetin. Cancer Res 56: 4904-4909, 1996.
10. Dimmock JR, Kandepu NM, Nazarali AJ, Kowalchuk TP, Motaganahalli N, Quail JW, Mykytiuk PA, Audette GF, Prasad L, Perjési P, Allen TM, Santos CL, Szydlowski J, De Clercq E, Balzarini J: Conformational and quantitative structure-activity relationship study of cytotoxic 2-arylidenebenzocycloalkanones. J Med Chem 42: 1358-1366, 1999.
11. Osaka M, Matsuo S, Koh T, Sugiyama T: Loss of heterozygosity at the N-ras locus in 7,12-dimethylbenz[α]anthracene-induced rat leukemia. Molecular Carcinogenesis 18: 206-212, 1997.
12. Kozma L, Kiss I, Nagy A, Szakáll Sz, Ember I: Investigation of c-myc and K-ras amplification in renal clear cell adenocarcinoma. Cancer Letters 111: 127-131, 1997.
13. Ember I, Kiss I, Ghodratollah N, Raposa T: Effect of ABVD therapeutic protocol on oncogene and tumor suppressor gene expression in CBA/Ca mice. Anticancer Res 18: 1149-1152, 1998.
14. Ember I, Kiss I, Gombkötô Gy, Müller E, Szcremi M: Oncogene and suppressor gene expression as a biomarker for ethylene oxide exposure. Cancer Detection Prev 22: 241-245, 1998.
15. Ember I, Kiss I, Vermes É: Early effect of cyclophosphamide on oncogene expression in vivo. In Vivo 12: 201-208, 1998.
16. Ember I, Kiss I, Pusztai Zs: Effect of 7,12-dimethylbenz[α]anthracene on onco/suppressor gene action in vivo: A short-term experiment. Anticancer Res 18: 445-448, 1998.
17. Ember I, Kiss I, Nowrasteh G: Different H2 haplotypes have strong influence on oncogene action. Anticancer Res 19: 1181-1186, 1999.
18. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Analytical Biochem 162: 156-159, 1989.
19. Al-Nakib TM, Perjési P, Varghese R, Meegan MJ: Benzylideneindanones and benzylidenebenzosuberones: Relationship between structure, antimycotic activity and acute toxicity. Med Principles Practice 6: 14-21, 1997.
20. Wiseman RW, Stewart BC, Grenier D, Miller EC, Miller JA: Characterization of c-Ha-ras protooncogene mutations in chemically induced hepatomas of the B6C3F1 mouse. Proc Amer Assoc Cancer Res 28: 147, 1987.
21. Stanley LA, Blackburn D, Deveraux S, Foley J, Lord PG, Maronpot RR, Orton TC, Anderson MW: Ras mutations in methylclofenapate-induced B6C3F1 and C57BUJ10 mouse liver tumours. Carcinogenesis 15: 1125-1131, 1994.
22. Toftgard R, Roop DR, Yuspa SH: Protooncogene expression during two-stage carcinogenesis in mouse skin. Carcinogenesis 6: 655-657, 1985.
23. Pelling JC, Ernst SM, Strawhecker JM, Johnson JA, Nairn RS, Slaga TJ: Elevated expression of Ha-ras is an early event in two-stage carcinogenesis in SENCAR mice. Carcinogenesis 9: 599-1602, 1986.
24. Pelling JC, Fisher SM, Neades R, Strawhecker J, Schweickert L: Elevated expression and point mutation of the Ha-ras protooncogene in mouse skin tumors promoted by benzyl peroxide and other promoting agents. Carcinogenesis 8: 1481-1484, 1987.
25. Wilson NM, Christou M, Tumer CR, Wrighton SA, Jefcoate CR: Binding and metabolism of benzo[α]pyrene and 7,12-dimethylbenz [α]anthracene by seven purified forms of cytochrome P-450. Carcinogenesis 5: 1475-1483, 1984.
26. Antstead GM, Wilson SR, Katzenellenbogen JA: 2-Arylindenes and 2-arylindenones: Molecular structures and considerations in the binding orientation of unsymmetrical nonsteroidal ligands to the estrogen receptor. J Med Chem 32: 2163-2171, 1989.
27. Bayer H, Batzl C, Hartmann RW, Mannschreck A: New aromatase inhibitors. Synthesis and biological activity of pyridyl-susbstituted tetralone derivatives. J Med Chem 34: 2685-2691. 1991.
28. Ember I, Kiss I, Faluhelyi Z: Gene expression changes as potential biomarkers of tumour bearing status in humans. Eur J Cancer Prev 7: 347-350, 1998.